Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells

2008 ◽  
Vol 14 (7) ◽  
pp. 1997-2005 ◽  
Author(s):  
Amit Verma ◽  
Sushovan Guha ◽  
Huamin Wang ◽  
Jansina Y. Fok ◽  
Dimpy Koul ◽  
...  
Pancreas ◽  
2012 ◽  
Vol 41 (8) ◽  
pp. 1306-1315 ◽  
Author(s):  
Hung Pham ◽  
Monica Chen ◽  
Hiroki Takahashi ◽  
Jonathan King ◽  
Howard A. Reber ◽  
...  

2011 ◽  
Vol 43 (5) ◽  
pp. 291 ◽  
Author(s):  
Yangsoon Lee ◽  
Su Jin Kim ◽  
Hye Jin Min ◽  
Ji Yoon Jo ◽  
Eun Hye Park ◽  
...  

2013 ◽  
Vol 144 (5) ◽  
pp. S-97
Author(s):  
Yixin Yao ◽  
Martin Canizales ◽  
Vijaya Ramachandran ◽  
Thiruvengadam Arumugam ◽  
Craig D. Logsdon ◽  
...  

2007 ◽  
Vol 5 (3) ◽  
pp. 241-249 ◽  
Author(s):  
Ugur Akar ◽  
Bulent Ozpolat ◽  
Kapil Mehta ◽  
Jansina Fok ◽  
Yasuko Kondo ◽  
...  

Autophagy ◽  
2007 ◽  
Vol 3 (5) ◽  
pp. 480-483 ◽  
Author(s):  
Bulent Ozpolat ◽  
Ugur Akar ◽  
Kapil Mehta ◽  
Gabriel Lopez-Berestein

2008 ◽  
Vol 294 (4) ◽  
pp. G899-G905 ◽  
Author(s):  
Jimmy Y. C. Chow ◽  
Hui Dong ◽  
Khai T. Quach ◽  
Phuoc Nam Van Nguyen ◽  
Kevin Chen ◽  
...  

Transforming growth factor-β (TGF-β) suppresses growth via the TGF-β-SMAD pathway but promotes growth in cancer cells with disrupted SMAD signaling and corresponds to an invasive phenotype. TGF-β also downregulates the tumor suppressor PTEN that is rarely mutated in sporadic pancreatic cancer; this downregulation may mediate cell proliferation and invasiveness, but the mechanism is unknown. Here, we examined whether TGF-β modulation of PTEN was mediated by protein kinase C (PKC). We have previously demonstrated that SMAD4-null BxPc-3 pancreatic cancer cells treated with TGF-β1 (10 ng/ml) suppressed PTEN expression and increased cell proliferation. TGF-β-treated cells were examined for PKC activation and its coupling to PTEN expression, utilizing pharmacological and knockdown methods. Calcium mobilization and cell migration were also examined. In BxPc-3 cells, only two PKC isoforms were activated by TGF-β, and PTEN downregulation by TGF-β was specifically mediated by PKC-α. In parallel, TGF-β rapidly induced an increase in cytoplasmic free calcium from intracellular stores, consistent with subsequent PKC-α activation. The TGF-β-induced increase in cell migration was blocked by knockdown of PKC-α. Thus calcium-dependent PKC-α mediates TGF-β-induced transcriptional downregulation of PTEN, and this pathway promotes cell migration in a SMAD4-null environment. The TGF-β-PKC-α-PTEN cascade may be a key pathway for pancreatic cancer cells to proliferate and metastasize.


Tumor Biology ◽  
2017 ◽  
Vol 39 (5) ◽  
pp. 101042831769912 ◽  
Author(s):  
Xiangxuan Zhao ◽  
Wei Sun ◽  
William M Puszyk ◽  
Shannon Wallet ◽  
Steve Hochwald ◽  
...  

Pancreatic cancer has one of the lowest survival rates of all cancers. The mechanism underlying chemo-resistance of pancreatic cancer is not well understood. Our previous article reported that small molecule YM155 induced apoptosis in pancreatic cancer cells via activation of death receptor 5. In this study, we aim to continuously address death receptor 5–mediated apoptosis in chemo-resistant pancreatic carcinoma. We found that in comparison to paired pancreatic cancer tissues and adjacent normal tissues, five of the six cancer tissues had downregulated death receptor 5 and upregulated Bcl-xL. Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL expression. Interestingly, pre-treatment with Bcl-xL inhibitor ABT263 reversed the insensitivity of panc-1 cells to lexatumumab or PF573228-induced apoptosis. Specific small interfering RNA-mediated gene silencing of Bcl-xL effectively sensitized pancreatic cancer cells to lexatumumab or PF573228-induced apoptosis. Furthermore, lexatumumab and PF573228 combination was shown to exhibit significant xenograft pancreatic tumor growth inhibition in SCID mice. Our data provide fundamental evidence to support the notion that lexatumumab and PF573228 co-treatment could be a potentially effective regime for patients with pancreatic cancer.


Sign in / Sign up

Export Citation Format

Share Document